within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX29_Brexanolone;
model Brexanolone 
   extends Pharmacolibrary.Drugs.ATC.N.N06AX29;

  annotation(Documentation(
    info ="<html><body><p>Brexanolone is a neuroactive steroid and a positive allosteric modulator of GABA-A receptors, used for the treatment of postpartum depression in adult women. It is currently FDA-approved for this indication and is administered as an intravenous infusion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult women with postpartum depression following the recommended clinical intravenous dosing regimen.</p><h4>References</h4><ol><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38993656/&quot;>https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Leader, LD, et al., &amp; VandenBerg, A (2019). Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations. <i>Pharmacotherapy</i> 39(11) 1105–1112. DOI:<a href=&quot;https://doi.org/10.1002/phar.2331&quot;>10.1002/phar.2331</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31514247/&quot;>https://pubmed.ncbi.nlm.nih.gov/31514247</a></p></li><li><p>Scott, LJ (2019). Brexanolone: First Global Approval. <i>Drugs</i> 79(7) 779–783. DOI:<a href=&quot;https://doi.org/10.1007/s40265-019-01121-0&quot;>10.1007/s40265-019-01121-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31006078/&quot;>https://pubmed.ncbi.nlm.nih.gov/31006078</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Brexanolone;
